A longitudinal genome-wide association study of anti-tumor necrosis factor response among Japanese patients with rheumatoid arthritis

Table 1 Patient characteristics at baseline

Characteristic	All patients (n = 444)
Age, years	56.4 ± 12.7
Sex, female	373 (84.0 %)
RA duration (years)	8.1 ± 8.5
Serum CRP (mg/l)	27.6 ± 27.9
Tender joint count	6 (3–11)
Swollen joint count	6 (3–10)
DAS28CRP3 score	4.6 ± 1.0
Disease activity
Mild (2.6 < DAS28 ≤ 3.2)	31 (7.0 %)
Moderate (3.2 < DAS28 ≤ 5.1)	282 (63.5 %)
Severe (DAS28 > 5.1)	131 (29.5 %)
Anti-TNF therapy
Etarnercept	172 (38.7 %)
Infliximab	242 (54.5 %)
Adalimumab	30 (6.8 %)
Other medications
Methotrexate	354 (79.7 %)
Prednisolone	283 (65.1 %)*^a
Anti-TNF naïve at baseline	419 (94.4 %)
Switching to a new anti-TNF agent at baseline	18 (4.1 %)
Ever smoker	94 (23.4 %)*^b
ACPA positive	330 (88.7 %)*^c
RF positive	337 (80.1 %)*^d

Results are shown as mean ± SD, median (IQR) or number (%). *Data for these variables were not available for all patients. Sample sizes were as follows ^a435, ^b402, ^c372, ^d421. RA rheumatoid arthritis, CRP C-reactive protein, Disease Activity Score in 28 joints DAS28, ACPA anti-citrullinated protein antibodies, RF rheumatoid factor

ISSN: 1478-6362